Penrose Harrison, Heller Sandra, Cable Chloe, Makboul Rania, Chadalawada Gita, Chen Ying, Crawford Susan E, Savkovic Suzana D
Department of Pathology and Laboratory Medicine, Tulane University School of Medicine, 1430 Tulane Ave SL-79, New Orleans, LA 70112, USA.
Department of Pathology and Laboratory Medicine, Tulane University School of Medicine, 1430 Tulane Ave SL-79, New Orleans, LA 70112, USA; Pathology Department, Assiut University, Assiut, Egypt.
Biochem Biophys Res Commun. 2016 Jan 15;469(3):370-6. doi: 10.1016/j.bbrc.2015.11.119. Epub 2015 Nov 30.
The proliferation of colon cancer cells is mediated in part by epidermal growth factor receptor (EGFR) signaling and requires sustained levels of cellular energy to meet its high metabolic needs. Intracellular lipid droplets (LDs) are a source of energy used for various cellular functions and they are elevated in density in human cancer, yet their regulation and function are not well understood. Here, in human colon cancer cells, EGF stimulates increases in LD density, which depends on EGFR expression and activation as well as the individual cellular capacity for lipid synthesis. Increases in LDs are blockaded by inhibition of PI3K/mTOR and PGE2 synthesis, supporting their dependency on select upstream pathways. In colon cancer cells, silencing of the FOXO3 transcription factor leads to down regulation of SIRT6, a negative regulator of lipid synthesis, and consequent increases in the LD coat protein PLIN2, revealing that increases in LDs depend on loss of FOXO3/SIRT6. Moreover, EGF stimulates loss of FOXO3/SIRT6, which is blockaded by the inhibition of upstream pathways as well as lipid synthesis, revealing existence of a negative regulatory loop between LDs and FOXO3/SIRT6. Elevated LDs are utilized by EGF treatment and their depletion through the inhibition of lipid synthesis or silencing of PLIN2 significantly attenuates proliferation. This novel mechanism of proliferative EGFR signaling leading to elevated LD density in colon cancer cells could potentially be therapeutically targeted for the treatment of tumor progression.
结肠癌细胞的增殖部分由表皮生长因子受体(EGFR)信号传导介导,并且需要持续的细胞能量水平来满足其高代谢需求。细胞内脂滴(LDs)是用于各种细胞功能的能量来源,在人类癌症中其密度升高,但其调节和功能尚未完全了解。在这里,在人类结肠癌细胞中,表皮生长因子(EGF)刺激脂滴密度增加,这取决于EGFR的表达和激活以及个体细胞的脂质合成能力。脂滴的增加被PI3K/mTOR和前列腺素E2(PGE2)合成的抑制所阻断,这支持了它们对特定上游途径的依赖性。在结肠癌细胞中,叉头框蛋白O3(FOXO3)转录因子的沉默导致SIRT6(脂质合成的负调节因子)的下调,进而导致脂滴包被蛋白2(PLIN2)增加,这表明脂滴的增加取决于FOXO3/SIRT6的缺失。此外,EGF刺激FOXO3/SIRT6的缺失,这被上游途径以及脂质合成的抑制所阻断,揭示了脂滴与FOXO3/SIRT6之间存在负调节环。通过抑制脂质合成或沉默PLIN2来消耗EGF处理后升高的脂滴,可显著减弱细胞增殖。这种导致结肠癌细胞中脂滴密度升高的增殖性EGFR信号传导新机制可能是治疗肿瘤进展的潜在治疗靶点。